Chairman Eliminates Nearly All Debt by Converting $105.8M into Equity
GALT sits 51% above its 52-week low of $2.025.
Summary
Galectin Therapeutics' Chairman converted $105.8 million in debt to equity, eliminating nearly all debt and strengthening the balance sheet ahead of a pivotal Phase 3 trial for its lead drug belapectin.
Key Events · Financing and Capital Events · GALT
-
Debt-to-Equity Conversion
Chairman Richard E. Uihlein converted $105.8 million in debt ($91M principal + $14.8M accrued interest) into 34,376,167 shares at a blended average price of $3.07 per share, eliminating nearly all of the company's debt.
-
Balance Sheet Transformation
The conversion removes a massive liability, significantly strengthening the balance sheet and reducing financial risk ahead of the pivotal Phase 3 belapectin trial. The company retains an undrawn $10 million credit facility.
-
Dilution Impact
Shares outstanding increased by approximately 52% to 100.8 million. Uihlein's beneficial ownership rises to ~44.3% actual and ~49.3% fully diluted, reflecting his increased equity stake and confidence.
-
Registration Obligation
The company must register the resale of the 34.4 million shares within 180 days, which could create an overhang if Uihlein decides to sell, though his conversion at market price suggests long-term commitment.
Analysis · GALT · Life Sciences
In a move that transforms the company's financial footing, Chairman Richard E. Uihlein converted $105.8 million of debt—comprising $91 million in principal and $14.8 million of accrued interest—into 34.4 million shares at an average price of $3.07, just a penny above today's $3.06. The transaction wipes out virtually all of Galectin's debt, turning a cash‑strapped biotech that faced going‑concern risk into a debt‑free entity with a much stronger balance sheet. While shares outstanding rise by about 52%, the dilution is more than offset by the removal of a massive liability. Uihlein's willingness to swap debt for equity at market prices signals deep conviction in the upcoming Phase 3 belapectin trial, for which the FDA recently agreed on the primary endpoint. The company still has an undrawn $10 million credit line and a cash runway to May 2027, but this move dramatically reduces financial risk ahead of a pivotal catalyst.
At the time of this filing, GALT was trading at $3.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.5M. The 52-week trading range was $2.03 to $7.13. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.